Treatment Information

Back

Melanoma treatment details. Biologic therapy.

Addenbrookes Hospital, Cambridge, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:3City/State/Province:Cambridge
Treatments:Biologic therapyHospital:Addenbrookes Hospital
Drugs:Journal:Link
Date:Oct 2010

Description:

Patients:
This study involved 34 patients with metastatic melanoma. The median patient age was 62 years and 62% were male.

Treatment:
Patients were given the biologic agent vatalanib, a tyrosine kinase inhibitor. This drug functions as an anti-angiogenesis agent and inhibits blood vessel growth in tumors.

Toxicities:
The highest toxicity grade reported was 3, mostly consisting of hypertension and elevated liver enzymes. Other reported toxicities included proteinuria, dizziness, fatigue, and nausea.

Results:
The median overall survival reported in this study was 6.5 months. Median progression-free survival was 1.8 months.

Support:
This study was partially supported by Bayer Schering Pharma, makers of vatalanib.

Correspondence: Dr. Pippa G. Corrie; email: [email protected]



Back